Venetoclax in the treatment of non-M3 acute myeloid leukemia:a rapid health technology assessment
10.12173/j.issn.1005-0698.202412044
- VernacularTitle:维奈克拉治疗非M3型急性髓系白血病的快速卫生技术评估
- Author:
Yazhuo ZHANG
1
;
Huiling LI
;
Yinyin DUAN
;
Yuye SHI
Author Information
1. 南京医科大学附属淮安第一医院药学部(江苏淮安 223300)
- Publication Type:Journal Article
- Keywords:
Venetoclax;
Non-M3 acute myeloid leukemia;
Rapid health technology assessment
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(3):314-323
- CountryChina
- Language:Chinese
-
Abstract:
Objective To rapidly evaluate the efficacy,safety,and cost-effectiveness of venetoclax(Ven)in non-M3 acute myeloid leukemia(AML),and to provide an evidence-based basis for rational clinical treatment.Methods PubMed,Cochrane Library,Embase,CNKI,WanFang Data databases,and relevant health technology assessment(HTA)websites were searched to collect relevant literature and reports on Ven treatment for non-M3 AML,with a search timeframe from the establishment of the database/website to November 1st,2024.Two researchers independently screened literature,extracted data,and assessed quality,and then qualitatively described and analyzed the results.Results A total of 11 pieces of literature were included,including 5 systematic reviews/Meta-analysis,4 pharmacoeconomic studies,and 2 HTA reports.In terms of efficacy,compared with the control group,non-M3 AML patients receiving Ven treatment had a higher clinical remission rate(P<0.05),a longer event-free survival(EFS)(P<0.05)and a similar or longer overall survival(OS)(P<0.05).Regarding safety,compared to Azacitidine(Aza)monotherapy,Ven+Aza resulted in a higher likelihood of febrile neutropenia in non-M3 AML patients(P<0.05).Non-M3 AML patients receiving Ven+low-dose cytarabine(LDAC)had a higher risk of developing thrombocytopenia compared with LDAC monotherapy(P<0.05).However,the early 30-day mortality rate was lower in the Ven+chemotherapy group than that in the chemotherapy alone group(P<0.05),presenting an acceptable security profile overall.In terms of cost-effectiveness,Ven was cost-effective in non-M3 AML patients compared with the control group.Conclusion Ven has manifested remarkable efficacy and acceptable security profile among patients with non-M3 AML,thus proving to be a medium to long-term cost-effective treatment modality.
